TCR2 Therapeutics Stock (TCRR): $5 Price Target From Goldman Sachs

By Amit Chowdhry ● Jan 19, 2022
  • The shares of TCR2 Therapeutics Inc (NASDAQ: TCRR) have received a $5 price target from Goldman Sachs. These are the details.

The shares of TCR2 Therapeutics Inc (NASDAQ: TCRR) have received a $5 price target from Goldman Sachs. And Goldman Sachs analyst Madhu Kumar downgraded TCR2 Therapeutics to a “Neutral” rating from a “Buy” rating while reducing the price target from $28.

Kumar was encouraged by interim Phase 1 data from the company’s lead TRuC auto gavo-cel for solid cancers. And Kumar is cautiously awaiting the complete Phase 1 data in the first half of this year to become more constructive on the program.

Kumar’s estimates for gavo-cel in malignant mesothelioma are well below consensus.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.